Eighty-four individuals, aged between 12 and 60 years old, affected by peanut allergy, were enrolled in a double-blind, placebo-controlled, randomized clinical trial (RCT) to test the anti-IgE monoclonal antibody TNX-901. Here, IGHE is linked to peanut allergic reaction.